Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis
The predictive role of [ 177 Lu]Lu-PSMA-617 SPECT/ CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary lesion-based analysis (EANM 2026) - Sep 29, 2026 - Abstract #EP-0908; "Our preliminary findings suggest that 1st cycle [¹⁷⁷Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters reflecting PSMA-expression may serve as promising early predictors of the single-lesion response to RLT." 
Metastases • Castration-Resistant Prostate Cancer • Prostate Cancer • FOLH1
https://www.sciencedirect.com/science/article/pii/S3051291326002855?via%3Dihub
 
R. Laudicella 1; G. Celesti 1; G. Ricciardello 1; A. Micali 2; F. Midili 2; A. Bucca 3; V. M. Ferro 3; M. Piergentili 4; M. Arco 1; D. Stanà 1; S. Russo 1; A. Brogna 2; B. Pagano 1; S. Baldari 1; I. A. Burger 5, 6; M. Bauckneht 4, 7; F. Minutoli 1
 
Sep 29, 2026
 
Prev Next